WINSTON-SALEM, N.C., May 31 /PRNewswire-FirstCall/ -- Targacept, Inc. , a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), today announced that J. Donald deBethizy, Ph.D., President and Chief Executive Officer, will present at the Bear Stearns Biotech Confab on Thursday, June 7, 2007 at 11:45 a.m. Eastern Daylight Time at the Boston Marriott Copley Place.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010517/CHTH002LOGO )
Dr. deBethizy's presentation will be webcast and accessible from the Investor Relations page of the Company's website at http://www.targacept.com. The webcast will also be available for replay on the Company's website for two weeks following the Confab. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled start time.
About Targacept
Targacept is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics(TM), a new class of drugs for the treatment of central nervous system diseases and disorders. Targacept's product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has product candidates in development for Alzheimer's disease and cognitive deficits in schizophrenia, pain, and depression and anxiety disorders, as well as multiple preclinical programs. Targacept is located in Winston-Salem, North Carolina. Targacept's news releases are available on its website at http://www.targacept.com.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20010517/CHTH002LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comTargacept, Inc.CONTACT: Alan Musso, VP and CFO of Targacept, Inc., +1-336-480-2186,alan.musso@targacept.com; or Michelle Linn of Linnden Communications,+1-508-419-1555, linnmich@comcast.net, for Targacept, Inc.
Web site: http://www.targacept.com/
